Pfizer Ventures

Activity from announced rounds

All recorded activity

Pfizer Ventures is the venture unit whose official portfolio includes TRIMTECH and TwoStep and whose partner Rana Al-Hallaq is identified in company materials.

Recorded funding activity

TwoStep develops targeted cancer therapies. TRIMTECH develops protein-degrading medicines for neurological disease, while Crossbow develops cancer antibodies. These relationships remain distinct from generic Pfizer corporate participation.

Sources
Rounds participated in
7
Confirmed lead rounds
0
6 roles undisclosed
New companies
7
First participation on record · 0 follow-on
Funding in participating rounds
$377.7M
7 disclosed · full round size, not this investor’s share

By stage

Seed2
Series A2
Series B1
Series C+1
Undisclosed1

By primary sector

Biotech7

By country

United States3
United Kingdom2
China1
France1

Rounds

7 in all activity
TwoStep Therapeutics

A peptide-targeting platform is advancing conjugate and radioligand therapies for solid tumors.

$62.5MSeries A
Role not disclosed
TRIMTECH Therapeutics

Develops small molecule therapies to degrade protein aggregates in neurodegenerative diseases

$47MSeed+
Role not disclosed
STORM Therapeutics

STORM Therapeutics develops cancer medicines that target enzymes responsible for chemical modifications to RNA.

$56MSeries C
Participant
TRex Bio

Develops precision immunoregulatory medicines based on tissue Treg biology

$50MUndisclosed
Role not disclosed
Enodia Therapeutics

Develops small-molecule therapies for targeted protein degradation at the point of synthesis

Role not disclosed